Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would say the cup starts at the last high of $0.31 only because this ticker has seen multiple reverse splits and share structures in the past.
Going back further, feels like the price action analysis isn’t quite apples to apples.
It seems buyouts have been for products/companies that are on the market or at the end of clinical trails (all three phases).
And I’ve noticed the purchased companies are private and easily raising multiple rounds of capital or are public and are already trading on Nasdaq.
My point is, the buyout dollars seem to be focused on finding growth as opposed to funding research. So I think we have a couple stages to move through before the risk/reward is there for a company to make an offer to RDGL.
I’ll be here either way.
Even with a fully diluted share count of 477m. These recent buyout numbers from
Big pharma place the PPS range between $2.93 and $8.59.
And I miscalculating anywhere or using an incorrect formula?
$1.4b - 4.1b buyout price / 447m shares
= $2.93 - $8.59 Price per share
“Big pharma has made plays for the space in the past year too, with Eli Lilly, Novartis and Bristol Myers Squibb signing deals ranging from $1.4bn to $4.1bn to acquire radiopharma specialists. ”
That’s a nice spread. Exciting time!
I think $0.31 is our next breakthrough price target, as it was the highest high since the reverse share split.
We get through that and make it a floor then we will be solid through approval and the waiting game that will be phase 1.
I expect the next month to chop between $0.24 and $0.31 once the broader market gets wind of the submission.
Love that our researchers are back. I remember a few years ago when we parsed every process detail to get any leg up on what to expect.
And the 18-24 months is only a timeline for the phase 1 portion of clinical trials.
It unlikely you will see $0.15 shares as we have built a floor around the $0.18 to 0.21 level.
I would simply accumulate in the next few weeks instead of trying to get the best price.
Every long on this board and many others will be scooping up any cheap share we can and at this point any thing under $0.20 is cheap in my mind. My average price is close to the $0.09 but as soon as I get paid again I’m buying another lot.
Summary of what had happened:
1) Company released news and PR about IDE submission
2) 30-day clock has begun for automatic approval (fingers crossed)
3) Company is raising $9m at $0.15 to compete phase one trails and operate over the next 18-24 months.
4) Price ran up 5x on submission rumor and is chopping sideways after a brief sell off.
I smell confidence in the water so if anyone is willing to donate their shares to my daughters college fund, please DM me!
These prices one last long!
You are right about this. The momentum has died down from submission expectation. It is frustrating, but it is what it is.
I figured our run up to $0.24 would be followed by a consolidation to the $0.21 level (which is where we are now).
Then once submission is announced, we will run up to the next high of 0.31 before more flipping and selling pressure.
I don’t think we break out fully until IDE approval is in hand and then it’s to the moon with FOMO and news outlets picking things up organically.
I asked this same question thinking it was more advantageous to do a dual disclosure. But I remember someone answering that it’s material information and is required to be disclosed.
My gut tells me the lawyers have said don’t drip feed anymore details to stay away from insider trading claims.
Think about it, “we will submit in 4 days” has way too much specificity no matter how much we may want it.
Well this is just a post submission guess. I think folks will be playing the trading game until final approval.
Either way I woke up today with the largest dose of adrenaline I’ve felt in a while. Feels like I’m about to step on the mat and go compete lol
Yeah this is exactly what we need. Strong hands willing to buy any shares that are being sold at a relative discount.
I still think the post-submission leg up will take us to $0.31 before we run into selling pressure again. There will be folks who sell after a 50% gain.
Oh wow, my sympathies and respect for coming out the other end.
Now let’s get you paid!
Thanks, I wasn’t sure because the top price targets he mentioned didn’t line up but yes the potential is unlimited.
Right. I think remember them saying there are like 18 different types. My wife had thyroid issues and I remember them telling her, swallow this radiation pill (and potentially lose teeth) or take the whole thing out. This will be third option for folks very soon.
Nice article!
“Prostate Cancer has dominated the [Solid tumor therapeutics] market with the most significant market share of 47% in 2023.”
Second indication maybe?!?
It's hard not to like this chart (Weekly RDGL). Notice how we are barely tapping the most recent high but haven't broken through, yet. Especially with the volume picking up, I think these levels will carry more weight. Once we are past $0.31, I consider it price discovery and the fuse is lit. If we can break it on submission news, then ideally we set it as a floor (while traders play their games) before phase 1 moon shot.
You have a right to your opinion and I have a right to mine.
I’m not SC8 and won’t be doing this song and dance with you, I just wanted to know if you had a leg to stand on for why you disliked me putting forth my thoughts.
I got nothing against you sir and am now opting out of this tirade.
We will both make a boatload of money and look back and laugh at all the pettiness incurred cuz our nerves are frayed.
Thanks plinter1, it’s all a hypothesis until the end of next week. Seems to me that unless you throw out $16 pps predictions, it means you are a fudster.
But, I figure instead of just throwing random numbers out there based on what we hope, why not see what the chart says.
So, I’m about direct communication. Are you saying I have an angle specifically? Check my posts, good sir, not one of them have been FUD. A little chart analysis never hurt anyone.
True! Lol, I’ve gotten into TA over the last few months and I’m by no means an expert.
I think it helps me keep my wits about me but I’ve been in RDGL since 2021.
It’s a steady grind up but without news the .242 zone is going to be the next hurdle point. This is pure technical analysis which has to be taken with a huge grain of salt since it’s a penny stock.
Every time frame except the weekly shows overbought which means we have run out of steam to push higher without news.
Once news drops then move up to .31 IMO.
After approval, who knows
It’s going to be hard with the flippers and those who bought in at the last top being flushed out.
The last top was around $0.24 so I expect us to tap that and consolidate lower above .20 until submission news occurs. It’s healthy they way we have moved up then sideways because it shows there are shareholders unwilling to sell at these levels where price action is sideways.
We have already seen the rumor run (from 0.05 to 0.20), so continued price action will be around the submission news pop then sell off to consolidate at what I hope will be around .31 until FDA approval news comes.
$0.31 is the high since the last stock split so liquidity is resting there and we will need to push through and hold at that price level to move even higher.
Once approval happens, who knows. These targets are for the next 7-15 days.
What ticker is this for. I only found FFIE
To All,
This will be my last post here, before we all make a boatload of money. Forgive me as it’s a long one. Been in since 2020. I’ve recently overweighted up to 40% into RDGL because the next SP catalyst is basically a sure thing. (I believe in the company but it won’t be sitting in my 401k for years lol)
With that I have a message to all our regulars:
A) A good leader of a company, never over promises and under delivers and the long haul folk know far too well how many times that’s happened in the past. Seems the team has learned their lesson, so a fairly frequent informal update (all the recent tweets) plus a firm time frame of submission (by end of Q2) without any silly intermediary updates that could get blown is just fine for us.
B) Technical analysis on this stock shows that a run up to 0.20 from 0.05, not too long ago, and a pull back plus consolidation around 0.15, is so healthy it’s not even funny. It’s a spring coiling for release. Pack your bags! Even if you bought right now, a trip back to 20 is money, right?
C) I never realized how serious these forum boys are. Our old friends left and they rotated in a new player with a new style and a new pain point to throw FUD around and everyone is getting gaslit and provoked. They come in neutral and ask a benign question and then start with the critiques that would sound reasonable to anyone new but are so apparently false to anyone that’s been here, even since Jan. Here’s the best bet. When FUDsters are found out, maybe just post and don’t reply. That way the Jackbutt isn’t referenced and highlighted over and over and over again. Lol they will respond no matter what anyway.
D) You can bet that those who bought the Reg-A are receiving comprehensive updates that are way better than a tweet. The fact that it was sold means that progress is being made. Unless you have run your own company, and actually raised capital and been beholden to shareholders whims, you have know idea how hard Dr. k and the team are working behind the scenes just to appease them.
E) I say “them” because I do not include us in the “need to appease batch.” Our collective “panty in wad” nature makes no noise whatsoever. We get the summarized version of what direct investors get in hour+ long convos.
F) Can you imagine the insane amounts of moving parts required to get all of this over the finish line? And yet there are those who sit and ask why the team isn’t spending all their time writing tweets and paying for PRs. What would you like your hard earned investment dollars to go to (I don’t have a dog in the isopet isn’t with it discussion so don’t even try it, I could care less). For me isopet is a dress rehearsal for the product, branding, vendor training and hospital onboarding. All of which can be ported over to radiogel
G) To all who know what the real deal is and only read this forum to make sure we don’t miss any big news, set your take profit order and don’t come back until June 20th lol.
GTLA - LFG - FTF (dm for what the last one means lol)
I highly doubt they will publish when the submission of the IDE and just release the fact that they receive IDE approval similar to the BDD announcement.
That way they don’t have anxious shareholders blowing them up for 30 days while they wait the clock out.
“After receiving FDA approval to conduct clinical trials we need formal approval from the Mayo Clinic IRB. In anticipation of this step and to help expedite the proccess we have submitted the Clinical Trial Protocol to their “gatekeeper” for comments.”
I took note of the last paragraph in the update.
To me this signals that they strongly believe they will receive full IDE approval in the next two quarters. It seems like they are trying to dot a lot of procedural i’s in order to submit this quarter or be ready to submit next quarter.
The IDE application won’t be submitted until after the next meeting so they can get feedback on their genotoxicity tests. Hopefully, other requirements don’t come to light in that meeting.
Sorry, I was responding to some one who mentioned BDD. I’ve been in RDGL since 2021 and I read the board everyday (guess I’m masochistic lol).
I’m just looking for some competitive tickers that were once in our “pre-submission” position to see how they performed post submission and post approval
Know of any?
What is the stock ticker for this? I can’t seem to find it and what was their underlying product?
Amen, the soundtrack will definitely sound different then. I’ll check back in with you in due time.
We could all just stop posting entirely for like a week and watch people argue with air. Just a thought.
MC,
We are in the exact same boat in so many ways. I can also be an emotional investor and I’ve also not been here as long as others.
I would venture to say this is one of the most personally researched stocks I’ve ever invested in so I’m super comfortable with the risk level despite the ups and downs….even our initial buy in and current cost averages are similar.
I respect the old heads who have more money in the game, more experience with the ups and downs but we shall all see it through, because we believe.
No, he can't. Buried deep in the quarterly update is the information regarding how expensive a true Phase 1 clinical trial is and that it will take 12-24 months.
He needs the smaller EFS study to go right so he can raise capital in order to complete the other study.
There has been a ton of digging done on this process and the language is there that gives us the timeframe we desire.
Granted, I could be jumping to conclusions but I think we are about to move into phase 4 of the EFS process.
To summarize from this article on page 22 (EFS Process)
1: Contact FDA
2: Submit initial pre-submission (basically a first draft of the IDE)
3: Submit additional pre-submissions with the goal of obtaining feedback and reaching an agreement on the investigational plan (protocol, endpoints, monitoring plan, informed consent)
4: Submit IDE with the goal of interacting with FDA review team to address any questions about the IDE AND Use the interactive review during the execution of the EFS to address any potential change in the device, the procedure, or the protocol.
We knew we were in phase 3 before because biocompatibility testing is explicitly mentioned as a part of phase 3 in this article and it was explicitly highlighted in the 9/20 PR.
We now know that that the Nov 30 meeting is to have the official word from FDA to move into phase 4 of the EFS process.
Fingers crossed that they submit before the end of the year and as per the article (page 25):
No, if you see at the bottom the following occurred:
1. On September 23, 2021, the reporting person exercised a warrant to purchase 150,000 shares of the Issuer's common stock. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 58,696 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 91,304 shares.
He didn't buy the warrants, he used the market sale of a portion of what he was owed to purchase the remaining about.
So he now owns 91K more shares than he did the day before.
That's a strong move, I think. Especially after the PR because it notes his own continued belief in the company. I like the fact that he has over 10 million shares and still wanted more.
You might be right on that and if so we are all in for a pleasant surprise in t-minus 20 days (or less).
Gonna go scrap something to buy more just in case.